Meeting
2020 ASCO Virtual Scientific Program
Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
Authors
Vicky Makker
Memorial Sloan Kettering Cancer Center, New York, NY
Vicky Makker , Matthew H. Taylor , Carol Aghajanian , Ana Oaknin , James Mier , Allen Lee Cohn , Margarita Romeo , Raquel Bratos , Marcia S. Brose , Christopher DiSimone , Mark Messing , Lea Dutta , Min Ren , Emmett V. Schmidt , Robert Orlowski , Jodi Alicia McKenzie , Kathryn Gillis , Antonio Casado Herraez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT02501096
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6083)
DOI
10.1200/JCO.2020.38.15_suppl.6083
Abstract #
6083
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
First Author: Christian Marth
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda
Poster
2018 ASCO Annual Meeting
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
First Author: Vicky Makker
Poster
2023 ASCO Annual Meeting
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
First Author: Manuel Rodrigues